Tags

Type your tag names separated by a space and hit enter

Helicobacter pylori seropositivity and subsite-specific gastric cancer risks in Linxian, China.
J Natl Cancer Inst 2001; 93(3):226-33JNCI

Abstract

BACKGROUND

Helicobacter pylori carriage (i.e., persistent exposure to the organism without gastric epithelial cell invasion) is an established risk factor for noncardia gastric cancer. However, its association with the risk of cancer of the gastric cardia is controversial. Consequently, we designed this prospective, nested case-control study to further explore the subsite-specific gastric cancer risks associated with H. pylori seropositivity (a surrogate marker for persistent exposure).

METHODS

A total of 99 patients with gastric cardia cancer, 82 patients with noncardia gastric cancer, and 192 cancer-free subjects were selected from among the participants (n = 29 584) of a nutrition intervention trial previously conducted in Linxian, China. H. pylori seropositivity was determined by assaying for the presence of H. pylori whole cell and CagA antibodies in baseline serum samples from all subjects. Seropositivity was defined as one or both serum assays being positive. Odds ratios (ORs) for subsite-specific gastric cancer were estimated by multivariate logistic regression analyses. All statistical comparisons were two-sided (alpha =.05).

RESULTS

H. pylori seropositivity rates for subjects with gastric cardia cancer, noncardia gastric cancer, and gastric cardia and noncardia cancers combined were 70% (P =.02), 72% (P: =.01), and 71% (P =.003) compared with 56% for cancer-free control subjects. OR estimates for H. pylori seropositivity were 1.87 (95% confidence interval [CI] = 1.10 to 3.17) for gastric cardia cancer, 2.29 (95% CI = 1.26 to 4.14) for noncardia gastric cancer, and 2.04 (95% CI = 1.31 to 3.18) for gastric cardia and noncardia cancers combined.

CONCLUSIONS

H. pylori seropositivity was associated with increased risks for both gastric cardia cancer and noncardia gastric cancer in this well-characterized cohort. Thus, H. pylori carriage may increase the risk of cancer throughout the stomach.

Authors+Show Affiliations

Cancer Prevention Studies Branch, Division of Clinical Sciences, National Cancer Institute, Bethesda, MD, USA. limburg.paul@mayo.eduNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

11158192

Citation

Limburg, P, et al. "Helicobacter Pylori Seropositivity and Subsite-specific Gastric Cancer Risks in Linxian, China." Journal of the National Cancer Institute, vol. 93, no. 3, 2001, pp. 226-33.
Limburg P, Qiao Y, Mark S, et al. Helicobacter pylori seropositivity and subsite-specific gastric cancer risks in Linxian, China. J Natl Cancer Inst. 2001;93(3):226-33.
Limburg, P., Qiao, Y., Mark, S., Wang, G., Perez-Perez, G., Blaser, M., ... Dawsey, S. (2001). Helicobacter pylori seropositivity and subsite-specific gastric cancer risks in Linxian, China. Journal of the National Cancer Institute, 93(3), pp. 226-33.
Limburg P, et al. Helicobacter Pylori Seropositivity and Subsite-specific Gastric Cancer Risks in Linxian, China. J Natl Cancer Inst. 2001 Feb 7;93(3):226-33. PubMed PMID: 11158192.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Helicobacter pylori seropositivity and subsite-specific gastric cancer risks in Linxian, China. AU - Limburg,P, AU - Qiao,Y, AU - Mark,S, AU - Wang,G, AU - Perez-Perez,G, AU - Blaser,M, AU - Wu,Y, AU - Zou,X, AU - Dong,Z, AU - Taylor,P, AU - Dawsey,S, PY - 2001/2/7/pubmed PY - 2001/4/3/medline PY - 2001/2/7/entrez SP - 226 EP - 33 JF - Journal of the National Cancer Institute JO - J. Natl. Cancer Inst. VL - 93 IS - 3 N2 - BACKGROUND: Helicobacter pylori carriage (i.e., persistent exposure to the organism without gastric epithelial cell invasion) is an established risk factor for noncardia gastric cancer. However, its association with the risk of cancer of the gastric cardia is controversial. Consequently, we designed this prospective, nested case-control study to further explore the subsite-specific gastric cancer risks associated with H. pylori seropositivity (a surrogate marker for persistent exposure). METHODS: A total of 99 patients with gastric cardia cancer, 82 patients with noncardia gastric cancer, and 192 cancer-free subjects were selected from among the participants (n = 29 584) of a nutrition intervention trial previously conducted in Linxian, China. H. pylori seropositivity was determined by assaying for the presence of H. pylori whole cell and CagA antibodies in baseline serum samples from all subjects. Seropositivity was defined as one or both serum assays being positive. Odds ratios (ORs) for subsite-specific gastric cancer were estimated by multivariate logistic regression analyses. All statistical comparisons were two-sided (alpha =.05). RESULTS: H. pylori seropositivity rates for subjects with gastric cardia cancer, noncardia gastric cancer, and gastric cardia and noncardia cancers combined were 70% (P =.02), 72% (P: =.01), and 71% (P =.003) compared with 56% for cancer-free control subjects. OR estimates for H. pylori seropositivity were 1.87 (95% confidence interval [CI] = 1.10 to 3.17) for gastric cardia cancer, 2.29 (95% CI = 1.26 to 4.14) for noncardia gastric cancer, and 2.04 (95% CI = 1.31 to 3.18) for gastric cardia and noncardia cancers combined. CONCLUSIONS: H. pylori seropositivity was associated with increased risks for both gastric cardia cancer and noncardia gastric cancer in this well-characterized cohort. Thus, H. pylori carriage may increase the risk of cancer throughout the stomach. SN - 0027-8874 UR - https://www.unboundmedicine.com/medline/citation/11158192/Helicobacter_pylori_seropositivity_and_subsite_specific_gastric_cancer_risks_in_Linxian_China_ L2 - https://academic.oup.com/jnci/article-lookup/doi/10.1093/jnci/93.3.226 DB - PRIME DP - Unbound Medicine ER -